Veeva：2025年生命科学应用商业内容内核的计划报告（英文版）

Commercial content managers have much to be excited about. The average days in review for content decreased by more than 25% to 16 days at U.S. biopharmas last year. EU companies held steady in the metric compared to the prior year. The number of review cycles was down across all markets globally. Now, commercial teams seeking to sustain momentum as they produce more high-quality content faster can adopt a standard taxonomy called the Commercial Content Kernel for Life Sciences. The content k